You M. Zhai
#79 Qingchun Road
Hangzhou, 310003, China
Hangzhou, 310003, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications
Phase I Trial of GPC3-Targeted TCR Fusion Construct, CT0180, in patients with Advanced Hepatocellular Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 21, 2026
Safety, pharmacokinetic, and pharmacodynamic characteristics of SK-08, a soluble guanylate cyclase activator, after oral administration in healthy participants: a randomized phase 1 trial.
Journal: BMC nephrology
Published: February 13, 2026
A Deep Learning-Driven Framework Integrating Organoid-Based Functional Validation Identifies Universal Neoantigens from Recurrent Glioma Mutations.
Journal: Cancer research
Published: June 24, 2025
Strategy and clinical benefit of first re-resection for recurrent adult-type diffuse glioma: A retrospective cohort analysis.
Journal: Med (New York, N.Y.)
Published: March 14, 2025
Population Pharmacokinetic Modeling Analysis of ASC10, a Novel Antiviral Agent Targeted COVID-19, in Chinese Healthy Subjects.
Journal: Drug design, development and therapy
Published: January 17, 2025
Retraction Note: Tumour microenvironment programming by an RNA-RNA-binding protein complex creates a druggable vulnerability in IDH-wild-type glioblastoma.
Journal: Nature cell biology
Published: January 17, 2025
Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects.
Journal: Expert opinion on investigational drugs
Published: July 11, 2024
Poliovirus receptor-based chimeric antigen receptor T cells combined with NK-92 cells exert potent activity against glioblastoma.
Journal: Journal of the National Cancer Institute
Published: July 04, 2023
Last Updated: 09/26/2026